Drug Trial Radar · NCT06670950
A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Nov 4, 2024
Primary completion
May 17, 2025
Study completion May 23, 2025
Sponsor
- Lead sponsor
- Synendos Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1 aims to investigate the relative bioavailability of a new formulation and to assess potential food effects following oral administration of SYT-510. Part 1 will then guide dosing in Part 2, a multiple dose study which aims to assess safety, tolerability and pharmacokinetic of multiple SYT-510 administrations.
Conditions
- Healthy
Interventions
SYT-510Drug
Oral formulation A fasted
SYT-510Drug
Oral formulation B fasted
SYT-510Drug
Oral formulation A fed
PlaceboDrug
Oral formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Maximum Observed Concentration (Cmax) of SYT-510Time frame: Up to 72 hours post-dose
- Part 1: Area under the concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of SYT-510Time frame: Up to 72 hours post-dose
- Part 1: AUC of SYT-510Time frame: Up to several days post last dose
- Part 2: Incidence and severity of treatment related adverse event, including abnormal laboratory events to evaluate the safety and tolerability profile of multiple ascending doses of SYT-510Time frame: Up to Day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Richmond Pharmacology Ltd
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.